Tag: WatchPAT
Itamar enhances WatchPAT
June 15, 2021HME News Staff
CAESAREA, Israel – Itamar Medical has enhanced its WatchPAT product line to include WatchPAT with SleepPath, a new service that allows subjective data to be collected from patients through the WatchPAT smartphone app, before and after the home sleep test. The company will offer the new service to sleep clinics, giving them access to digital documentation in one report that combines sleep study metrics and patient self-reported data, replacing traditional paper documentation. Itamar Medical...
Itamar's WatchPAT gets nod from Blues
November 6, 2019HME News Staff
CAESAREA, Israel - Itamar Medical has received coverage for its WatchPAT as a home sleep apnea diagnostic test by Blue Shield of California (BSC) and the Blue Cross Blue Shield Federal Employee Plan (BCBS FEP). The inclusion of WatchPAT and PAT technology follows an assessment, Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome, recently released by Blue Cross Blue Shield Association Evidence Street. “The inclusion of WatchPAT as a recommended test for sleep apnea in the BCBS...
Itamar Medical: New fee schedule advances WatchPAT
November 16, 2018HME News Staff
CAESAREA, Israel - The recently released 2019 fee schedule from CMS should support broad use of Itamar Medical's WatchPAT technology, the company says. WatchPAT uses peripheral arterial tone (PAT) technology to provide cardiologists and sleep physicians in the United States with accurate sleep diagnoses. “We believe that the new CMS fee schedule validates the clinical value of our sleep tests for patients and may significantly advance utilization of our sleep tests in the U.S. market,”...
Short takes: Breg, WatchPAT
August 4, 2016HME News Staff
Breg, an integrated solutions provider, announced the launch of Vision 5.0, the latest iteration of its DME workflow management software. Vision automates and optimizes in-house bracing and supplies programs…The FDA has approved WatchPAT, a home sleep test diagnostic device for sleep apnea, for use among patients as young as 12. The decision follows similar approvals in Japan and Europe, and expands the device's previous use in the U.S. for 17 and older.